Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics, May 2021, Springer Science + Business Media,
DOI: 10.1186/s12931-021-01733-9.
You can read the full text:



The following have contributed to this page